Simulations Plus Earnings Call Transcripts
Fiscal Year 2026
-
Revenue grew 8% to $24.3M in Q2, with strong software and services performance, improved gross margins, and robust cash reserves. AI integration and pharma collaborations are driving future growth, though management remains cautious due to macro risks.
-
The platform is expanding from point solutions to an integrated AI-enabled ecosystem, with a focus on cross-selling, value-based pricing, and deeper pharma engagement. FY 2026 growth is guided at 0%-4%, with stronger performance expected in the second half and significant AI-driven revenue upside anticipated in FY 2027.
-
The meeting covered board elections, auditor ratification, an equity plan amendment, and executive compensation vote frequency. All proposals passed with strong support, and no shareholder questions were submitted during the Q&A.
-
A unified, AI-enabled ecosystem is being developed to support the full drug development lifecycle, leveraging cloud, validated science, and integrated services. Fiscal 2026 guidance is reaffirmed, with new revenue streams and cross-selling expected to drive long-term growth and margin expansion.
-
Revenue declined 3% to $18.4M, with strong services growth offsetting a 17% software drop. Gross margin improved to 59%, and guidance for FY26 remains unchanged, anticipating 0–4% revenue growth and a software mix of 57–62%.
Fiscal Year 2025
-
Fiscal 2025 saw 13% revenue growth and strong adjusted EBITDA, despite Q4 declines and a $77.2M impairment. FY26 guidance projects flat to modest growth, with aggressive pricing and AI-driven product enhancements planned. Backlog and cash flow remain robust.
-
The company leverages decades of biosimulation and AI expertise to support drug development from discovery through post-approval, with a strong regulatory position and proprietary data. Strategic realignment and regulatory trends, such as reduced animal testing, are expected to drive future growth.
-
The event highlighted ongoing growth in biosimulation, expansion into clinical operations via acquisition, and the integration of AI and cloud technologies. Despite industry headwinds, software renewals remain strong, and regulatory trends support future adoption.
-
Revenue grew 10% to $20.4M, driven by the Pro-ficiency acquisition, but organic revenue declined 4% amid market headwinds and a major impairment charge. Software remained resilient, while services faced delays and cancellations, prompting a downward revision in guidance.
-
Q2 FY2025 revenue rose 23% year-over-year, with strong software growth and robust bookings, though service project starts remain delayed. Guidance for FY2025 is reaffirmed, with a significant backlog and a $5M MC contract win expected to boost H2 results.
-
Four biosimulation software platforms and consulting services are driving strong growth, with Monolix and Pro-ficiency leading in market share gains. The Pro-ficiency acquisition is expanding margin potential and client access, while fiscal 2025 guidance anticipates steady industry growth and improved profitability.
-
The company is focused on efficiency and recurring software revenue, with a strong 95% renewal rate and a 60/40 software-to-services split. The Pro-ficiency acquisition expands market reach and is expected to add $15–$18 million in revenue, supporting growth and margin improvement.
-
Revenue grew 31% year-over-year, driven by strong software performance and contributions from new business units. Backlog and bookings were robust, supporting a positive outlook, while guidance for fiscal 2025 was reaffirmed. Adjusted EBITDA margin and integration efforts remain on track.
Fiscal Year 2024
-
Client budget discussions and bookings signal cautious optimism for 2025, with cost constraints persisting but integration of Pro-ficiency expanding market reach and financial performance. Operational improvements and a unified sales approach support growth and margin targets.
-
Fiscal 2024 saw 18% revenue growth and strong EPS, driven by software upgrades and the Pro-ficiency acquisition, which doubled the addressable market. Fiscal 2025 guidance projects 28%–33% revenue growth, with improved margins and continued integration of recent acquisitions.
-
Biosimulation is a growing, high-margin market, with recent expansion into clinical operations and commercialization through the Pro-ficiency acquisition, doubling TAM to $8 billion. The business maintains strong recurring software revenue, targets 10–15% organic growth, and is attracting increased analyst attention due to its consistent profitability and AI-driven solutions.
-
Q3 revenue grew 14% year-over-year, with strong software and services performance and adjusted EPS of $0.19. The Proficiency acquisition is on track, expected to be accretive in 2025, and the company reaffirmed its fiscal 2024 guidance.
-
The $100 million acquisition of Pro-ficiency doubles the total addressable market to $8 billion, expands capabilities across the drug development continuum, and is expected to be accretive to fiscal 2025 EPS. Integration will focus on cross-selling and leveraging established pharma relationships.